GenoMed Debt-Free After Forgiveness of $1 Million Loan

GenoMed Debt-Free After Forgiveness of $1 Million Loan 


ST. LOUIS, March 15  /PRNewswire-FirstCall/ -- GenoMed, Inc.  (BULLETIN BOARD:
GMED) , a Next Generation Disease Management(TM) company that uses its expertise
in genomics to improve patient outcomes, today announced that it has secured
financing for over $1.5 million to date, triggering the forgiveness of nearly
$1.2 million in debt and accrued interest. GenoMed is now essentially
debt-free.

GenoMed received its final installment of a total of $900,000 in equity
financing from Advanced Optics Electronics, Inc. (OTC:ADOT) (BULLETIN BOARD:
ADOT)  last week, as well as $380,000 to complete a maximum of $500,000 equity
investment by Research Capital. GenoMed has also begun receiving payments from
Pierpoint Investissements SA, a venture capital group based in Switzerland. As a
result, Research Capital has agreed to forgive nearly $1.2 million in debt and
accrued interest because GenoMed was successful in raising at least $1.5 million
before December 2004.

Dr. David Moskowitz, GenoMed's Chairman CEO, said, "We are delighted to have
obtained enough financing already this year to be able to retire our debt to
Research Capital. The money raised so far has completely turned our financial
situation around, and has enabled us to begin our genomics research program in
earnest."

Dr. Moskowitz is a Harvard and Oxford trained physician, and is a noted pioneer
in the field of medical genomics.  He has been recognized for his groundbreaking
treatmentof diseases associated with the angiotensin I- converting enzyme, such
as chronic renal failure due to hypertension or type II diabetes.

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already
made possible. GenoMedis a Next Generation Disease Management(TM) company whose
mission is to improve patient outcomes by identifying the genetic pathways that
cause disease. The Company is currently marketing its treatment for what it
believes is the major starting point for most age- related diseases.

Safe Harbor Statement

This press release contains forward-looking statements, including those
statements pertaining to GenoMed, Inc.'s (the Company's) finances and
treatments. The words or phrases "ought to," "should," "could," "may," or
similar expressions are intended to identify "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Actual
results could differ materially from those projected in the forward- looking
statements as a result of a number of risks and uncertainties, including but not
limited to: (a) whether we will have sufficient ongoing financing to conduct our
research and development; (b) the success of our marketing efforts; and (c) our
research anddevelopment being subject to other economic, regulatory,
governmental, and technological factors. Statements made herein are as of the
date of this press release and should not be relied upon as of any subsequent
date. Unless otherwise required by applicable law, we specifically disclaim any
obligation to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such
statement. 

DATASOURCE: GenoMed, Inc.



CONTACT: David W. Moskowitz, MD, MA, FACP, of GenoMed Inc.,

[phone],  ; or Paul Knopick of E & E

Communications, [phone],  



Web site:  http://www.genomedics.com/ 

Copyright